FI82266C
(fi)
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Foerfarande foer framstaellning av il-2 -mutein.
|
US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
AU3285989A
(en)
|
1987-11-25 |
1989-06-14 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
WO1997003703A1
(en)
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
EP1032428B1
(en)
|
1997-11-20 |
2003-06-18 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
DK1100830T3
(da)
|
1998-07-28 |
2004-01-19 |
Micromet Ag |
Heterominiantistoffer
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
HU227347B1
(en)
|
1999-10-04 |
2011-04-28 |
Novartis Vaccines & Diagnostic |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
US20020041865A1
(en)
*
|
2000-01-20 |
2002-04-11 |
Richard Austin |
Methods for treating tumors
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
CN100503639C
(zh)
*
|
2001-05-03 |
2009-06-24 |
默克专利有限公司 |
重组肿瘤特异性抗体及其应用
|
AU2002312410A1
(en)
|
2001-06-08 |
2002-12-23 |
Target Protein Technologies, Inc. |
Tissue-specific endothelial membrane proteins
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−2突然変異体
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
MXPA04005266A
(es)
|
2001-12-04 |
2004-10-11 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada.
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
EP1539960B1
(en)
|
2002-09-09 |
2010-04-28 |
Hanall Pharmaceutical Co., Ltd. |
Protease-resistant modified interferon alpha polypeptides
|
WO2004041865A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Stabilized single domain antibodies
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
US20070202097A1
(en)
|
2003-03-10 |
2007-08-30 |
Krissansen Geoffrey W |
Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
WO2005014642A2
(en)
|
2003-07-21 |
2005-02-17 |
Transgene S.A. |
Novel multifunctional cytokines
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
JP2007515185A
(ja)
|
2003-12-22 |
2007-06-14 |
カイロン コーポレイション |
免疫応答障害に対する処置ストラテジーのための診断法としてのFcレセプター多型の使用
|
AP2006003689A0
(en)
|
2004-01-09 |
2006-08-31 |
Pfizer |
Antibodies to MAdCAM
|
US20060234205A1
(en)
|
2004-03-05 |
2006-10-19 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
CA2566363C
(en)
|
2004-05-19 |
2014-12-16 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
US8815235B2
(en)
|
2004-06-02 |
2014-08-26 |
Jan E. Schnitzer |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
ES2432141T3
(es)
|
2005-01-27 |
2013-11-29 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimientos para tratar carcinoma de células renales
|
KR20070108402A
(ko)
|
2005-02-15 |
2007-11-09 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
화학요법제와 il-2 및 선택적으로 항-cd20 항체의조합물을 사용하여 임파종을 치료하는 방법
|
WO2006096490A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
CN101213297B
(zh)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
MX2007014474A
(es)
*
|
2005-05-17 |
2008-02-07 |
Univ Connecticut |
Composiciones y metodos para inmunomodulacion en un organismo.
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
EA031202B1
(ru)
|
2006-06-06 |
2018-11-30 |
Янссен Вэксинс Энд Превеншн Б.В. |
Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
WO2008085987A2
(en)
|
2007-01-09 |
2008-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
EP2842570B1
(en)
|
2007-03-07 |
2020-05-06 |
UTI Limited Partnership |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
WO2009002380A2
(en)
|
2007-06-26 |
2008-12-31 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
AU2008329530A1
(en)
|
2007-11-28 |
2009-06-04 |
Universite De Montreal |
PD-1 modulation and uses thereof
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
WO2010029434A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
ES2657220T3
(es)
|
2008-10-02 |
2018-03-02 |
Aptevo Research And Development Llc |
Proteínas de unión multi-diana antagonistas de CD86
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
KR20110086101A
(ko)
|
2008-10-21 |
2011-07-27 |
메르크 파텐트 게엠베하 |
방사선 및 면역사이토카인으로의 암 치료
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
WO2010117423A2
(en)
|
2009-03-31 |
2010-10-14 |
Duke University |
A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
|
JP2013501817A
(ja)
|
2009-08-14 |
2013-01-17 |
アメリカ合衆国 |
胸腺産出の増大およびリンパ球減少症の治療のためのil−15の使用
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
ME02505B
(me)
|
2009-12-29 |
2017-02-20 |
Aptevo Res & Development Llc |
Heterodimerni vezujući proteini i njihove upotrebe
|
WO2011110642A2
(en)
|
2010-03-10 |
2011-09-15 |
Genmab A/S |
Monoclonal antibodies against c-met
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
HUE054318T2
(hu)
|
2010-11-12 |
2021-08-30 |
Nektar Therapeutics |
IL-2 molekularész konjugátumai és polimer
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
EP3075745B1
(en)
|
2011-02-10 |
2018-09-05 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
ES2676878T3
(es)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Diseño de armazón de heteromultímero multivalente y constructos
|
BR112013023151A2
(pt)
|
2011-03-11 |
2020-09-15 |
Assistance Publique - Hôpitaux De Paris |
interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
|
EP3766513A1
(en)
|
2011-03-11 |
2021-01-20 |
Assistance Publique Hôpitaux de Paris |
Use of low dosage il-2 for treating vasculitis
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
EP2726504A1
(en)
|
2011-05-27 |
2014-05-07 |
Dutalys |
Antibodies with improved folding stability
|
CN103764665A
(zh)
|
2011-06-28 |
2014-04-30 |
怀特黑德生物医学研究所 |
使用分选酶安装用于蛋白质连接的点击化学柄
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
US20140248372A1
(en)
|
2011-09-19 |
2014-09-04 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
CN104080811B
(zh)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
IL307989A
(en)
|
2012-04-27 |
2023-12-01 |
Novo Nordisk As |
Human CD30 ligand antigen-binding proteins
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
EP2866826A1
(en)
|
2012-06-27 |
2015-05-06 |
Arthrogen BV |
Combination for treating an inflammatory disorder
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
WO2014023679A1
(en)
|
2012-08-07 |
2014-02-13 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
CA2893981C
(en)
|
2012-12-05 |
2021-11-16 |
Shiow-Her Chiou |
Chemokine-cytokine fusion protein and its use
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
WO2014150600A2
(en)
|
2013-03-15 |
2014-09-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
EA201890895A1
(ru)
*
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
EP4119662A1
(en)
|
2013-05-10 |
2023-01-18 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
WO2014194784A1
(zh)
|
2013-06-06 |
2014-12-11 |
合肥立方制药股份有限公司 |
人源抗纤连蛋白ed-b结构域的抗体及其用途
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
CN106604934A
(zh)
|
2014-06-11 |
2017-04-26 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
RS59789B1
(sr)
|
2014-07-21 |
2020-02-28 |
Delinia Inc |
Molekuli koji selektivno aktiviraju regulatorne t ćelije u tretmanima autoimunih bolesti
|
WO2016016859A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
ES2847311T3
(es)
|
2014-08-05 |
2021-08-02 |
MabQuest SA |
Reactivos inmunológicos que se unen a PD-1
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
CA2962275C
(en)
|
2014-10-23 |
2019-11-05 |
Singh Biotechnology, Llc |
Single domain antibodies directed against intracellular antigens
|
EP4382535A2
(en)
|
2014-12-15 |
2024-06-12 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
ES2881484T3
(es)
|
2014-12-22 |
2021-11-29 |
Pd 1 Acquisition Group Llc |
Anticuerpos anti-PD-1
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
CA2916283A1
(en)
*
|
2015-01-09 |
2016-07-09 |
Pfizer Inc. |
Dosage regimen for madcam antagonists
|
US20170369871A1
(en)
|
2015-01-12 |
2017-12-28 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10336824B2
(en)
|
2015-03-13 |
2019-07-02 |
Cytomx Therapeutics, Inc. |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
|
CN107921122B
(zh)
|
2015-04-08 |
2021-08-10 |
索伦托药业有限公司 |
与cd38结合的抗体治疗剂
|
US10293058B2
(en)
|
2015-04-22 |
2019-05-21 |
Curevac Ag |
RNA containing composition for treatment of tumor diseases
|
EP3292140B1
(en)
|
2015-05-05 |
2022-04-20 |
Rubicon Biotechnology LLC |
Cancer immunotherapeutic
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
WO2016187226A1
(en)
|
2015-05-18 |
2016-11-24 |
Ab Initio Biotherapeutics, Inc. |
Sirp polypeptide compositions and methods of use
|
KR20240013282A
(ko)
|
2015-06-10 |
2024-01-30 |
이뮤너티바이오, 인크. |
암을 치료하기 위한 변형된 nk-92 세포
|
CN108337890B
(zh)
|
2015-06-23 |
2021-10-15 |
纪念斯隆-凯特琳癌症中心 |
新型pd-1免疫调节剂
|
CN108135848A
(zh)
|
2015-06-30 |
2018-06-08 |
纳米提克斯有限责任公司 |
与清除颗粒相关的组合物和方法
|
KR20180034619A
(ko)
|
2015-07-29 |
2018-04-04 |
나노틱스 엘엘씨 |
가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법
|
WO2017023780A1
(en)
|
2015-07-31 |
2017-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting cd56-positive tumors
|
TWI617319B
(zh)
|
2015-09-01 |
2018-03-11 |
免疫功坊股份有限公司 |
用以治療病理性血栓的融合蛋白
|
KR20180049080A
(ko)
|
2015-09-11 |
2018-05-10 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
AU2016341241B9
(en)
|
2015-10-22 |
2021-11-18 |
Iltoo Pharma |
Pharmaceutical compositions of IL-2
|
US20170232070A1
(en)
|
2015-10-23 |
2017-08-17 |
Richard P. Junghans |
Combination Methods for Immunotherapy
|
CN109071648B
(zh)
|
2015-10-23 |
2022-07-19 |
辉瑞有限公司 |
抗il-2抗体及其组合物和用途
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
ES2873846T3
(es)
|
2015-11-19 |
2021-11-04 |
Revitope Ltd |
Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
|
EP3383422B1
(en)
|
2015-12-02 |
2021-08-11 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
CA2997406C
(en)
|
2015-12-09 |
2024-05-28 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
EP3395366B1
(en)
|
2015-12-21 |
2023-11-22 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Drug design method, obtained drug and application thereof
|
AU2017206618A1
(en)
|
2016-01-11 |
2018-07-05 |
Universität Zürich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
US11723932B2
(en)
|
2016-01-11 |
2023-08-15 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
CN108473569B
(zh)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
JP7292877B2
(ja)
|
2016-01-14 |
2023-06-19 |
イントレクソン・アクトバイオテイクス・エヌブイ |
1型糖尿病を処置するための組成物および方法
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
EP4059957A1
(en)
|
2016-02-05 |
2022-09-21 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
JP7220458B2
(ja)
|
2016-02-05 |
2023-02-10 |
ワシントン・ユニバーシティ |
標的サイトカインデリバリーのための組成物および方法
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
EP3211000B1
(en)
|
2016-02-25 |
2019-01-30 |
Provecs Medical GmbH |
Novel immunostimulating vector system
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
US10988512B2
(en)
|
2016-03-10 |
2021-04-27 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US10898576B2
(en)
|
2016-03-16 |
2021-01-26 |
Yanhui Xie |
Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease
|
EP3430055B1
(en)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
JP6732041B2
(ja)
|
2016-04-12 |
2020-07-29 |
フィロジェン ソチエタ ペル アツィオーニ |
炎症性免疫サイトカインおよびキメラ抗原受容体(car)−t細胞を含む併用治療
|
ES2864095T3
(es)
|
2016-04-15 |
2021-10-13 |
Philogen Spa |
Anticuerpo anti-tenascina no glicosilado
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
WO2017190684A1
(zh)
|
2016-05-06 |
2017-11-09 |
王牧林 |
白细胞介素组合及其用途
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
US20200316118A1
(en)
|
2016-05-19 |
2020-10-08 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
CN109478421B
(zh)
|
2016-05-25 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
剂量方案设计相关的材料与方法
|
MX2018014602A
(es)
|
2016-05-27 |
2019-06-10 |
Etubics Corp |
Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
|
AU2017274540B2
(en)
|
2016-06-03 |
2020-04-16 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
AU2017272356A1
(en)
|
2016-06-03 |
2018-12-20 |
Etubics Corporation |
Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases
|
WO2017210579A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
EP3475413B1
(en)
|
2016-06-22 |
2024-02-14 |
David Klatzmann |
Genetically modified t lymphocytes
|
CN109689086A
(zh)
|
2016-07-11 |
2019-04-26 |
国家生物技术研究所公司 |
具有延长的血清半衰期的融合蛋白
|
WO2018014006A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for flavivirus vaccination
|
WO2018014008A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
US10576167B2
(en)
|
2016-08-17 |
2020-03-03 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
SG11201901271VA
(en)
|
2016-08-19 |
2019-03-28 |
Brooklyn Immunotherapeutics Llc |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
US11453726B2
(en)
|
2016-09-15 |
2022-09-27 |
Quadrucept Bio Limited |
Multimers, tetramers and octamers
|
KR102257154B1
(ko)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
CA3036564A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
JP2019532640A
(ja)
|
2016-09-29 |
2019-11-14 |
ナントクエスト インコーポレイテッド |
免疫原性が低下したhlaクラスi欠損nk−92細胞
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
CN109890406A
(zh)
|
2016-11-10 |
2019-06-14 |
尼克塔治疗公司 |
肿瘤免疫治疗性治疗方法
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
CA3044416A1
(en)
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
EP3555125A4
(en)
|
2016-12-15 |
2019-11-20 |
The Brigham and Women's Hospital, Inc. |
TISSUE BIOLOGICAL PRODUCTS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS
|
EP3558339B1
(en)
|
2016-12-22 |
2024-01-24 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
EP3565604A4
(en)
|
2017-01-04 |
2020-09-09 |
Nanotics, LLC |
ELIMINATING PARTICLE ASSEMBLY PROCESSES
|
JP7118072B2
(ja)
|
2017-01-06 |
2022-08-15 |
イミュニティーバイオ インコーポレイテッド |
Cd96/tigit発現が低下した遺伝子改変型nk-92細胞
|
CA3049163A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
EP3568150A4
(en)
|
2017-01-10 |
2020-12-02 |
Xcella Biosciences, Inc. |
POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
|
EP3577132A4
(en)
|
2017-02-03 |
2021-03-10 |
University of Pittsburgh - of The Commonwealth System of Higher Education |
ONCOLYTIC VIRUS THERAPY
|
EP3583125A2
(en)
|
2017-02-16 |
2019-12-25 |
Sonnet Bio Therapeutics |
Albumin binding domain fusion proteins
|
WO2018160877A1
(en)
|
2017-03-01 |
2018-09-07 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
CA3056630A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
BR112019017329A2
(pt)
|
2017-04-03 |
2020-04-14 |
Hoffmann La Roche |
imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
WO2018189220A1
(en)
|
2017-04-13 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
MX2018015599A
(es)
|
2017-05-10 |
2019-05-16 |
Wellstat Immunotherapeutics Llc |
Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.
|
MX2019013202A
(es)
|
2017-05-10 |
2020-01-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
|
WO2018213192A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
CN111010866A
(zh)
|
2017-05-24 |
2020-04-14 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
EP3630813A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
JP2020522516A
(ja)
|
2017-06-05 |
2020-07-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
|
CN110891605A
(zh)
|
2017-06-07 |
2020-03-17 |
希沃尔拜克治疗公司 |
免疫调节化合物的抗体缀合物及其用途
|
SG11201912010XA
(en)
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
EP3638700A4
(en)
|
2017-06-14 |
2021-04-21 |
Dingfu Biotarget Co., Ltd |
PROTEINOUS HETERODIMER AND USE OF IT
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
EP3675892A4
(en)
|
2017-07-03 |
2021-10-06 |
Torque Therapeutics, Inc. |
IMMUNOSTIMULATORY FUSION MOLECULES AND THEIR USES
|
US20200149053A1
(en)
|
2017-07-12 |
2020-05-14 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
AU2018309166B2
(en)
|
2017-08-03 |
2022-12-08 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
KR20200064062A
(ko)
|
2017-08-04 |
2020-06-05 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
WO2019032663A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
PD-1 AND PD-L1 BINDING AGENTS
|
CN117924493A
(zh)
|
2017-08-09 |
2024-04-26 |
奥里尼斯生物科学有限公司 |
Clec9a结合剂及其用途
|
CA3069930A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Cd8 binding agents
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CA3072816A1
(en)
|
2017-08-18 |
2019-02-21 |
Gritstone Oncology, Inc. |
Antigen-binding proteins targeting shared antigens
|
WO2019046815A1
(en)
|
2017-08-31 |
2019-03-07 |
Poseida Therapeutics, Inc. |
TRANSPOSON SYSTEM AND METHODS OF USE
|
CN111315768A
(zh)
|
2017-09-07 |
2020-06-19 |
库尔生物制药有限公司 |
具有缀合位点的t细胞调节性多聚体多肽及其使用方法
|
CA3070484A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTATION POLYPEPTIDES AND THEIR METHODS OF USE
|
JP2020532987A
(ja)
|
2017-09-08 |
2020-11-19 |
ポセイダ セラピューティクス,インコーポレイティド |
キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
|
JP2020534837A
(ja)
|
2017-09-27 |
2020-12-03 |
シギロン セラピューティクス, インコーポレイテッドSigilon Therapeutics, Inc. |
活性細胞を含む方法、組成物、及び移植可能な要素
|
EP3689903A4
(en)
|
2017-09-30 |
2022-01-12 |
Hefei Lifeon Pharmaceutical Co. Ltd. |
FIBRONECTIN B DOMAIN BINDING PROTEIN
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
CN111670051B
(zh)
|
2017-11-08 |
2024-06-25 |
亚飞(上海)生物医药科技有限公司 |
生物分子偶联物及其用途
|
WO2019092504A1
(en)
|
2017-11-13 |
2019-05-16 |
Extremochem, Lda. |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
SG11202004457XA
(en)
|
2017-11-17 |
2020-06-29 |
Iovance Biotherapeutics Inc |
Til expansion from fine needle aspirates and small biopsies
|
KR20200086722A
(ko)
|
2017-11-21 |
2020-07-17 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
EP3746103A4
(en)
|
2017-12-06 |
2022-03-30 |
The Board of Trustees of the Leland Stanford Junior University |
PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2
|
KR20200097275A
(ko)
|
2017-12-06 |
2020-08-18 |
팬디온 테라퓨틱스, 인코포레이티드 |
Il-2 뮤테인 및 그 용도
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNTOLERANCE
|
CA3082204A1
(en)
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
MX2020006689A
(es)
|
2017-12-20 |
2020-11-06 |
Poseida Therapeutics Inc |
Composiciones de vcar y metodos de uso.
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
CN111868079A
(zh)
|
2017-12-27 |
2020-10-30 |
协和麒麟株式会社 |
Il-2变体
|
CN111819198A
(zh)
|
2017-12-28 |
2020-10-23 |
尤利乌斯·马克西米利安维尔茨堡大学 |
具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白;TRAAFFIAA)
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
US20210052727A1
(en)
|
2018-01-24 |
2021-02-25 |
Beijing Percans Oncology Co., Ltd. |
Cytokine fusion proteins
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
BR112020018049A2
(pt)
|
2018-03-07 |
2020-12-29 |
Poseida Therapeutics, Inc. |
Composições de cartirina e métodos para uso
|
US20210260163A1
(en)
|
2018-03-09 |
2021-08-26 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
CN112654363A
(zh)
|
2018-07-09 |
2021-04-13 |
瑟罗泽恩公司 |
组织特异性wnt信号增强分子和其用途
|
WO2020020783A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Il2 agonists
|
JP2022501433A
(ja)
|
2018-09-18 |
2022-01-06 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的化された免疫寛容
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
WO2020163646A1
(en)
|
2019-02-08 |
2020-08-13 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
CN114728179A
(zh)
|
2019-08-19 |
2022-07-08 |
潘迪恩运营公司 |
利用pd-1激动剂的靶向免疫耐受
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
EP4107189A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations Inc |
TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
|
AU2021327225A1
(en)
|
2020-08-19 |
2023-03-23 |
Pandion Operations, Inc. |
Multi-paratopic anti-PD-1 antibodies and uses thereof
|
EP4229097A2
(en)
|
2020-10-16 |
2023-08-23 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|
EP4229078A2
(en)
|
2020-10-16 |
2023-08-23 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|